Oral Anticoagulants in Epistaxis Patients

Oral Anticoagulants in Epistaxis Patients - OAC bei Epistaxis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014339

Enrollment

540

Registered

2018-05-18

Start date

2018-04-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R04.0 D68.35

Interventions

Group 1: All patients treated stationary due to Epistaxis as main diagnosis from 01.01.2011 to 01.01.2018 and take phenprocoumon more then 6 months Group 2: All patients treated stationary due to Epis

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with a minimum age of 18 years that were treated stationary with the diagnosis epistaxis between 01.01.2011. - 01.01.2018 in the Hospital SANA Kliniken Leipziger Land, Klinikum Borna

Exclusion criteria

Exclusion criteria: The exclusion criteria were: active malignant disease, known genetic coagulopathy, liver disease and/ or failure, active respiratory infection, perforation of the nasal septum, postoperative bleeding after nasal surgery including septumplasty, septorhinoplasty or sinus surgery

Design outcomes

Secondary

Measure	Time frame
Using the Hospital Information System (HIS) a retrospective analysis will be performed from 01.01.2011 to 01.01.2018. The sec. outcomes are location of epistaxis, recurrence rate	—

Primary

Measure	Time frame
Using the Hospital Information System (HIS) a retrospective analysis will be performed from 01.01.2011 to 01.01.2018. The prim. outcomes are lenght of hospitalization in days, therapy and if necessary surgical intervention	—

Countries

Germany

Contacts

Public ContactPetar Stankovic

HNO Klinik, SANA Kliniken Leipziger Land

petar.stankovic@sana.de03433/21-1475

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026